![Hisaharu Momoshima](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profil
Hisaharu Momoshima is currently working as an Audit & Supervisory Board Member at DCI Partners KK.
Prior to this, he worked as an Audit & Supervisory Board Member at Daiwa Corporate Investment Co., Ltd. from 2018 to 2023.
Postes actifs de Hisaharu Momoshima
| Sociétés | Poste | Début |
|---|---|---|
DCI Partners KK
 DCI Partners KK Investment ManagersFinance DCI Partners is an active manager which provides financing for early stage capital requirements and spin-out or carve-out opportunities. The firm focuses on biotech start-ups centered on the therapeutic field in Japan and Taiwan. | Comptroller/Controller/Auditor | - |
Anciens postes connus de Hisaharu Momoshima
| Sociétés | Poste | Fin |
|---|---|---|
Daiwa Corporate Investment Co., Ltd.
 Daiwa Corporate Investment Co., Ltd. Investment ManagersFinance Daiwa Corporate Investment invests in companies located in Japan. The firm focuses on a broad range of sectors and Industries. It participates in buyout, early and growth stage transactions. | Comptroller/Controller/Auditor | 01/08/2023 |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
4
Relations au 1er degré
2
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Daiwa Corporate Investment Co., Ltd.
Daiwa Corporate Investment Co., Ltd. Investment ManagersFinance Daiwa Corporate Investment invests in companies located in Japan. The firm focuses on a broad range of sectors and Industries. It participates in buyout, early and growth stage transactions. | Finance |
DCI Partners KK
DCI Partners KK Investment ManagersFinance DCI Partners is an active manager which provides financing for early stage capital requirements and spin-out or carve-out opportunities. The firm focuses on biotech start-ups centered on the therapeutic field in Japan and Taiwan. | Finance |
